
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%
Percentage of Subjects
95.0%
94.0%
89.8%
88.5%
92.4%
91.2%
Preferred Injection (n=100)*
Preferred Injection for Long-Term Use (n=100)†
Preferred Injection (n=98)*
Preferred Injection for Long-Term Use (n=104)†
Preferred Injection (n=198)*
Preferred Injection for Long-Term Use (n=204)†
Received Alendronate, Then Denosumab
Received Denosumab, Then Alendronate
Total